Consequently, the introduction of abemaciclib marks a transformative shift from conventional chemotherapy or endocrine monotherapy to innovative targeted combination therapy, heralding a new era in targeted therapy for HR+/HER2- BC (5). The gene discussed is ERBB2; the disease is breast cancer.